Cyclacel Pharmaceuticals Inc (CYCCP.OQ)
16 May 2017
* Cyclacel pharmaceuticals reports first quarter 2017 financial results
* Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update
* Intra-Cellular Therapies provides corporate update on schizophrenia program
BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140
* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140
* Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results
Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.
Feb 23 Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.
Feb 23 Cyclacel Pharmaceuticals Inc said its experimental drug failed in a late-stage study on patients aged 70 years or more with newly diagnosed acute myeloid leukemia.
* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia
* Intra-Cellular Therapies Inc- on January 4, 2017, co's unit entered into a supply agreement with Siegfried Evionnaz SA- SEC filing Source: (http://bit.ly/2jALlxx) Further company coverage:
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,818||+31.00|
|DAIICHI SANKYO COMPANY, LIMITED (4568.T)||¥2,443||-0.50|
|Eisai Co., Ltd (4523.T)||¥5,982||+24.00|
|Pfizer Inc. (PFE.N)||$32.14||+0.02|
|Johnson & Johnson (JNJ.N)||$127.52||+0.26|
|Merck & Co., Inc. (MRK.N)||$64.55||+0.51|
|Roche Holding Ltd. (ROG.S)||CHF267.90||--|
|Roche Holding Ltd. (RO.S)||CHF267.25||-0.50|
|Bayer AG (BAYGn.DE)||€118.05||--|
|Bayer AG (BAYE.F)||--||--|